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Abstract 
 
It has been previously shown that cysteine-deleted tachyplesin (CDT) and its many 
analogs display antibacterial effects. However, little has been said about its possible 
anticancer effects and which analogs serve as the best inhibitors of the growing cancer 
cells. This research focused on CDT and four of its analogs: All D-CDT, Reverse D-
CDT, Reverse CDT, and Serine-Control CDT. MTT assays against the A549 
adenocarcinoma lung cancer cell line showed All D-CDT to be the most effective analog 
in preventing cancer cell growth. Hyaluronidase and apoptosis assays were performed to 
better understand the mechanism by which the All D-CDT is preventing cancer cell 
survival. From this data it was seen that the All D-CDT analog inhibits cancer cell growth 
via a hyaluronan interaction but it does not induce cellular apoptosis. This makes the 
analog of CDT a prospective treatment for cancer. 
 
 
 
 
 
 
 
 
 
 
iii		
Table of Contents 
Abstract .................................................................................................................................. ii 
List of Tables ......................................................................................................................... iv 
List of Figures ........................................................................................................................ v 
Chapter 1: Introduction .......................................................................................................... 1 
 1.1 Antimicrobial Peptides ........................................................................................ 1 
  1.1.1 Cell Death Initiation ............................................................................. 1 
 1.2 Cysteine-Deleted Tachyplesin ............................................................................. 6 
  1.2.1 Analogs of CDT .................................................................................... 7 
Chapter 2: Materials and Methods ......................................................................................... 10 
 2.1 Solid Phase Peptide Synthesis ............................................................................. 10 
 2.2 Peptide Purification ............................................................................................. 13 
 2.3 Cell Culture .......................................................................................................... 13 
 2.4 Seeding and Peptide Dosing of the A549 Cells ................................................... 14 
  2.4.1 MTT Assay ........................................................................................... 17 
  2.4.2 Hyaluronidase Assay ............................................................................ 18 
  2.4.3 Apoptosis Assay ................................................................................... 18 
Chapter 3: Results and Discussion ........................................................................................ 20 
 3.1 Peptide Synthesis and Purification results ........................................................... 20 
 3.2 MTT Assay Results ............................................................................................. 21 
 3.3 Hyaluronidase Assay Results .............................................................................. 26 
 3.4 Apoptosis Assay Results ..................................................................................... 29 
Chapter 4: Future Work ......................................................................................................... 32 
iv		
References ............................................................................................................................. 34 
List of Tables 
Table               Page 
Table 1: CDT Peptide Sequences with HPLC purities .......................................................... 20 
Table 2: The measured IC50 of the analogs of CDT .............................................................. 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v		
List of Figures 
Figure               Page 
Figure 1: The Caspase-3 Apoptotic pathway ........................................................................ 3 
Figure 2: Different Permeable Pathways of AMPs ............................................................... 5 
Figure 3: Schematic of Solid Phase Peptide Synthesis .......................................................... 12 
Figure 4: Peptide serial dilution process with the well concentrations ................................. 16 
Figure 5: Reduction of MTT tetrazolium to formazan product ............................................. 17 
Figure 6: Cell viability plot of the All D form of CDT ......................................................... 21 
Figure 7: Plot of the Reverse-D form of CDT ....................................................................... 22 
Figure 8: A549 cell viability of different CDT analogs ........................................................ 23 
Figure 9: Cell viability plot of the All D form of CDT after hyaluronan degradation .......... 27 
Figure 10: Cell viability plot of CDT after hyaluronan degradation ..................................... 28 
Figure 11: Percentage of A549 apoptosis increase as a function of increasing All D-CDT 
concentration  ........................................................................................................................ 31 
 
 
1		
Chapter 1: Introduction 
1.1 Antimicrobial Peptides 
 Cancer is still one of the leading causes of death in the United States. At the start 
of 2017, there were a reported 1.66 million cancer cases being faced in the country 
(National Institutes of Health, 2017). Alternative treatments have been sought by health 
professionals due to the lack of success of commonly used treatments such as 
chemotherapy, radiation therapy, immunotherapy, and hormone therapy (American 
Cancer Society, 2017). Through different areas of research, biological anticancer 
molecules have come to the forefront of cancer studies. In particular, antimicrobial 
peptides (AMPs) have gained attention.  
The history of the research on AMPs dates back to the 1930s and has progressed 
into the modern era (Gaspar et al., 2013). These molecules were hypothesized to be 
important immune defenses due to their presence within frog skin, known to hold the first 
round of defense against unwanted pathogens (Krisch, 2017). Now they have been found 
in several different animals, including humans, with multiple regions of origin within the 
organisms. More recently, these molecules have gained the interest of researchers due to 
the excessive prescription of antibiotics, which has led to the evolution of 
microorganisms that have become much more difficult to kill as they mutate and grow 
immune to antibiotic treatments (Center for Disease Control and Prevention, 2017).  
Researchers have suggested AMPs to be a likely successor to more traditional 
antibiotics (Gaspar et al., 2013). AMPs fight diseases effectively for many reasons. They 
are amphipathic, which allows them to permeate through most lipid membranes across 
any region of the body. They can survive in the different pH ranges of the body, 
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depending on the specific amino acid residues that make up the structure. They are also 
mainly composed of alternating hydrophobic regions and those with positive charges, 
made up by the amino acid residues such as Arg and Lys (Wood et al., 2013). Typically, 
AMPs are secondarily arranged into alpha helices and beta sheets; but they can also fold 
into other secondary shapes (Wood et al., 2013). An additional component of AMPs is 
that they vary in size and structure (10—500+ amino acids in length). This comes with 
both positive and negative impacts. It is possible that certain sizes may exclusively affect 
bacteria while another exclusively affects cancer. The efficacy of these molecules may 
also be due to size differences (Wood et al., 2014). The research required here would be 
extensive, as the trends would likely vary from one type of AMP to another. 
 
1.1.1 Cell Death Initiation 
Mammalian cells can undergo programmed cell death either extrinsically or 
intrinsically. The extrinsic pathways are initiated through cell surface molecules that 
affect the cell membrane leading to a cascade of signals within the cell. The intrinsic 
pathways typically involve signaling from the mitochondrion, which can also create an 
internal signal cascade. Both pathways are regulated and carried out by the cleavage of 
caspases (McDonald et al., 2003). The activation of a caspase can come from growth 
factor depletion, the activation of the Fas/Apo-1 receptor cell death pathway, or exposure 
to anticancer substrates. Figure 1 shows a schematic for the different pathways and 
ultimate result of the caspase-3 apoptotic pathway.  
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This programmed cell death is part of cellular regulation and equilibrium between 
synthesis and destruction. Programmed cell death, which can be initiated by AMPs, is 
also a way of fighting disease (Hoskin et al., 2008).  
Each route of cell destruction, via AMPs, involves cell membrane 
permeabilization by the peptides. Figure 2 shows the different AMP permeabilization 
pathways: carpet model, barrel stave, toroidal pore, and detergent-like. Given that AMPs 
are small and positively charged, they have a strong affinity for the negatively charged 
components of bacterial and cancer cell membranes, which allows for the accumulation 
of peptides into the cell barrier (Chen et al., 2005). The collection of AMPs on the 
membrane initiates one of the destruction pathways that have been previously described 
by others and follow here. The carpet model involves a covering of the peptide on the cell 
	Figure	1:	The	Caspase-3	Apoptotic	pathway	
4		
membrane until a certain concentration is reached (Chen et al., 2005). The carpet model 
is thought to be the precursor phase to all the other destructive pathways (Chen et al., 
2005). Once the threshold concentration is met, one of three possible membrane-
disabling pathways can begin. The barrel stave mode involves an aggregation of peptide 
creating a channel that allows for extracellular transport of ions and cell leakage 
(Bacalum et al., 2015). The toroidal pore is an extension from the barrel stave in that it 
incorporates phospholipid head groups, from the membrane, into the channel pore (Chen 
et al., 2005). The detergent-like mode, which can become an extension of the toroidal 
pore mode, is a micelle-like aggregation of peptides that detach fragments of the cell 
membrane (Chen et al., 2005). It is thought that these pathways can bring about 
programmed cell death in an extrinsic manner or via necrosis. The cellular interactions 
are possible due to the size and the amphipathic characteristics of the AMPs. Smaller 
AMPs can create rapid attraction and release, which can quickly initiate a death sequence 
without allowing the disease to familiarize itself with the peptide (Bacalum et al., 2015). 
This disallows the chance for the bacterial cell to adapt to the antimicrobial peptide 
leading to greater longevity and efficacy of prospective treatments (Hoskin et al., 2008).  
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Hyaluronan is another component of interest with regards to initiating cell death via 
AMPs. Hyaluronan is an oligomer of N-acetyl-D-glucosamine and glucuronic acid, found 
in synovial fluid and the extracellular matrix of most biologic tissues. It is produced in 
dendritic cells with a very large size ranging from 2 × 105 to 1 × 108 Da.  (Kogan et al., 
2006). Hyaluronan allows stabilization, communication, and growth of the cells it 
adheres to—its relationship with apoptosis has been studied previously via interactions 
with CD44. When CD44, another cell surface molecule, is bound to hyaluronan, 
programmed cell death is more likely to occur than when they are unbound (Kogan et al., 
2006).  When CD44 is unable to bind to hyaluronan, the cell becomes resistant to 
programmed cell death (Kogan et al., 2006). Others have found that hyaluronan levels are 
elevated in human tissues with cancer (Kultti et al., 2012). Since it has been suggested 
that the role played by hyaluronan involves anchorage-independent growth, proliferation 
Figure	2:	Different	Permeable	Pathways	of	AMPs	(Hoskin	et	al.,	2008)	
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ability, metastasis induction, increased adhesion and migration, or a protection against the 
immune system, it’s a valuable source of study when trying to understand the efficacy of 
AMPs against cancer (Kultti et al., 2012).  
 
1.2 Cysteine-Deleted Tachyplesin 
  Tachyplesin is an antimicrobial peptide derived from the hemocytes of horseshoe 
crabs (Shi et al., 2006; Ding et al., 2015). It can inhibit growth on both Gram-negative 
and Gram-positive bacteria (Nakamura et al., 1988). When unmodified, it has a positive 
charge of +7 and a short chain of 17 amino acids (KWCFRVCYRGICYRRCR). It also 
has hydrophobic traits to go along with its cationic properties. This allows tachyplesin to 
interact with the bacterial cell membrane, which has been found to occur via selective 
binding to the lipopolysaccharides (LPS). Tachyplesin naturally forms a beta-hairpin 
structure that is reinforced by the disulfide linkages of the cysteine residues (Wood et al., 
2014; Ramamoorthy et al., 2006). Initial studies of this peptide have shown antibacterial 
properties (Wood et al., 2014), all of which relate to the general characteristics of a good 
antimicrobial peptide (see section 1.1). In addition to having antibacterial traits, this 
peptide also showed an activation of hemolysis (the rupturing of red blood cells). This 
creates a dilemma. Although the antibacterial effects are welcome, the induction of 
hemolysis can cause damage to host cells (Ramamoorthy et al., 2006; King et al., 2014). 
To avoid this effect, development of different tachyplesin analogs was of interest, 
specifically analogs with low minimum inhibitory concentrations and no hemolysis 
activation. This spawned the discovery of cysteine-deleted tachyplesin (CDT, King et al., 
2014). 
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With only 13 residues present, (KWFRVYRGIYRRR), CDT has advantages over 
its parent compound since it is cheaper and easier to synthesize.  It is also assumed to be 
linear since it lacks the two disulfides of tachyplesin, which originally maintained the 
beta-hairpin motif. Previous research groups, including ours, have studied CDT and 
published substantial data on its antibacterial efficacy (Wood et al., 2014; Ramamoorthy 
et al., 2006). The initial benefits found for CDT are comparable to the traits it shared with 
its unmodified predecessor. It maintained the +7 charge as well as the hydrophobicity, 
but was found to have a diminished hemolytic effect. It also retained its ability to bind 
selectively to LPS, displaying its antibacterial properties (Wood et al., 2014). By having 
these traits CDT was identified as a viable candidate for further manipulation in structure, 
and further study of its efficacy in other areas of human cell death and bacterial infection; 
cancer research was one area that CDT had not yet been evaluated until this work. 
The goal of this research was to discover if CDT had anticancer properties. If so, 
we wanted to know what was the mechanism behind CDT’s anticancer properties.  
Through this process we believed we could discover structural improvements by 
manipulating the peptide’s residues and creating different CDT analogs. I hypothesized 
that if CDT had anticancer properties it was working through a relationship with 
hyaluronan that was inhibiting the binding of CD44 and thusly initiating an extrinsic 
programmed cell death pathway (apoptosis). 
  
1.2.1 Analogs of CDT 
 There has been a copious amount of research done demonstrating the 
effectiveness of tachyplesin and CDT analogs in the fight against different forms of 
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bacterial cells and cancer. It has been seen that tachyplesin can arrest cell growth at the 
G0/G1 phase (Li et al., 2003), induce death and differentiation of glioma stem cells (Ding 
et al., 2015), and bind overexpressed hyaluronan commonly found in cancer (Kultti et al., 
2012). From that standpoint, we set out to further manipulate the sequence of CDT to 
better understand what makes it capable of combating cancer (and even raising the 
question of whether it could be made an even better combatant). It is possible to test the 
efficacy of a peptide by manipulating/rearranging its amino acid residues. Each amino 
acid typically exists naturally in the L-form. This is simply the “left-handed” version. In 
some instances, the D-form (or the “right-handed form”) is found in nature—specifically 
in neuropeptides from amphibians, venoms, and the cell walls of bacteria (Lifetein, 2017) 
– but the D-form of amino acids is rarely found in animal peptides. Even so, studies have 
shown that the potency of a peptide can increase by using D-form amino acids (Kreil, 
1997).  This is often due to increased half-life because cellular enzymes do not recognize 
and degrade them (Luo et al., 2010). 
 Another option for rearrangement is to reverse the sequence of the amino acids 
for peptide synthesis. This helps to show whether the efficacy of the peptide’s anticancer 
effects is due to the specific sequence order of amino acids, or if it is more nonspecific. 
With peptides that bind to receptors, sequence reversal is not usually tolerated, but since 
some of the effects of antimicrobial peptides are more nonspecific membrane destructive 
effects, it is possible that sequence direction is not important, only the alternating 
hydrophobicity and positively charged regions (Hoskin et al., 2008). With the reverse 
sequence, it is also possible to create a reverse D-amino acid sequence. In this case, the 
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amino acid sequence is reversed and also made in the D-form rather than the L-form, 
combining the two modifications. 
 A serine-control peptide was synthesized by replacing the lysine and arginine 
residues with serine residues. This was done in the hopes of adjusting the amphipathic 
traits of CDT, going from the very basic and positively charged regions to the neutral but 
polar serine. This should lead to a loss in the electrostatic properties of the arginine, and 
therefore create an inability to bind to the negatively charged cellular components 
associated with cancer. This could then be used as a negative control for the system. 
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Chapter 2: Materials and Methods 
2.1 Solid Phase Peptide Synthesis 
 Solid phase peptide synthesis is the process of synthesizing a peptide through the 
use of polymer beads that contain binding sites necessary for attaching the C-terminal 
amino acid, which then is built one residue at a time toward the N-terminus. This is a 
step-wise process in which any sequence of amino acids can be added to synthesize the 
desired peptide. The peptide remains attached to the solid support as byproducts are 
washed away in solution at each step.  It can then be detached from the resin and isolated. 
The Fmoc (fluorenylmethyloxycarbonyl) protected amino acids were purchased 
from AnaSpec (Fremont, CA), Bachem Americas, Inc. (Torrance, CA), and Synthetech 
(Albany, OR). The HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate) coupling agent was purchased from Bachem Americas, Inc. The 
MBHA linker resin was purchased from Midwest Biotech, Inc. (Fishers, IN). Solvents 
and the deprotecting agents were purchased from Sigma Aldrich (St. Louis, MO). 
Each desired amino acid was added to the growing chain in conjunction with 
HBTU, which acted as a coupling agent between the amino acid and the growing peptide 
chain. It formed an activated ester with the incoming amino acid to ensure better 
coupling.  Protecting groups were required in this process to ensure that the correct 
functional groups reacted to form the amide binds and side reactions would be limited. 
The general scheme of solid phase peptide synthesis is an ordered process: attachment of 
C-terminal amino acid to the polymer linkerà deprotection of the alpha amineà 
coupling of next amino acid (formation of peptide bond)à deprotection of the new N-
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terminal amineà repeat coupling until all residues are added and the sequence is 
complete.  There are washes after each step. 
 Each amino acid used had the Fmoc protecting group attached as well as 
appropriate side chain protection, and the chain was built using Rink amide p-methyl 
benzhydryl amine (MBHA) resin (0.64 mmoles/g), on a 0.1 mmole scale. 
 The Fmoc protecting groups must be cleaved after each coupling step of the 
synthesis; this required a base, and the most commonly used one is piperidine. A 20% 
mixture of this base in N,N-dimethylformamide (DMF) solvent was used for 
deprotection, and DMF was used to wash after each step. The peptide synthesis was 
carried out on a PS3 Automated Peptide Synthesizer manufactured by Protein 
Technologies (Tuscon, AZ). 
 After all of the necessary amino acids had been attached and the final Fmoc group 
had been cleaved, the peptide chain was cleaved from the resin.  This also removed 
remaining side chain protecting groups. This required a cocktail of chemical components. 
Nine mL of TFA was the cleavage agent, and 0.50 mL of a phenol scavenger with 0.50 
mL of water were used to protect the peptide from side reactions that may have occurred 
due to the cleavage. The solution was mixed for two hours at room temperature and then 
filtered to remove the remaining resin. 
 Figure 3 shows the described process of solid phase peptide synthesis in a 
schematic form. 
 In order to precipitate the peptide from the solution, cold diethyl ether was added 
to the mixture. The solid peptide was then filtered from the solution and dissolved in a 
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70% mixture of acetonitrile in water before it was frozen in an acetone/dry ice bath. Then 
the product was lyophilized, or freeze-dried, for the next 24 hours.  
  
 
 
 
 
 
 
 
Figure	3:	Schematic	of	Solid	Phase	Peptide	Synthesis	
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2.2 Peptide Purification 
 Reverse phase high performance liquid chromatography (HPLC) was performed 
on a Waters analysis instrument (Milford, MA). A Phenomenex (Torrance, CA) Jupiter 
C18 column (2.2 x 25.0 cm, 10 mL/min) was used to purify the peptide with a linear 
gradient of 10% acetonitrile (0.1% TFA)/water (0.1% TFA) to 50% acetonitrile (0.1% 
TFA)/water (0.1% TFA) over a two hour period. The detector was set for 280 nm due to 
the tyrosine present in the peptide, rather than the general peptide bonds (214 nm) that 
could be present apart from the desired product. Fractions that were part of the same 
chromatographic peaks were collected and combined. Lyophilization was repeated to 
purify the peptide further. The desired product had a purity >99% by HPLC peak 
integration analysis. A JEOL electrospray mass spectrometer with a time of flight mass 
analyzer, set at 3500V, was used to confirm molecular weight of the peptides (see Table 
1 in Chapter 3: Results). 
 
 
2.3 Cell Culture 
 The A549 adenocarcinoma human alveolar basal epithelial cell line is commonly 
used in anticancer research. It is a representative of non-small cell lung cancer, a type of 
cancer that is typically untreatable (Lynch et al., 2004). The adenocarcinoma human 
alveolar basal epithelial cells were purchased from ATCC (Manassas, USA). They were 
cultured in Dublecco’s Modified Eagle Medium (DMEM). This media was supplemented 
with 10% fetal bovine serum (FBS) and 10 mg/mL of penicillin and streptomycin. They 
were incubated at 37 °C with 5% CO2 in humidified air. The cell media was purchased 
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from Invitrogen. The trypLE (a cell dissociation enzyme similar to trypsin) and 
phosphate buffered solution (PBS) were purchased from Thermo Fisher. 
 When the A549 cell line is cultured a monolayer is formed, which becomes 
adherent to the base of the culture flask. This type of monolayer growth allows for the 
calculation and uniform distribution of the cells within a 96-well plate. 
 
2.4 Seeding and Peptide Dosing of the A549 Cells 
 The A549 cells were incubated in a T-25 flask and allowed to grow with media 
(see section 2.3) over a period of 3—5 days, providing new media as necessary for 
continued growth. The amount of days was varied in order to maintain the appropriate 
confluency of adherent cells in the T-25 flask. When the flask reached a level of 80—
100% confluence (distribution of cells adherent to the base of the flask) the old media 
was removed and the cells were washed with PBS solution in order to remove waste by-
products (remaining media). After removal of the media the cells were detached by 
adding TrypLE. The flask was incubated for ten minutes at 37 °C, which sped up the 
detachment of the cells from the base of the flask. The detached cells were transferred 
into a 15 mL centrifuge tube. The cells were harvested by centrifugation at 600 RPM. 
The cell pellet was then re-suspended in 2.5 mL of PBS. 
 This created a pellet of cells in the centrifuge tube that could be approximated to 
2.5 million cells based on the surface volume of the T-25 flask initially used to grow the 
cells. This allowed for the calculation of desired number of cells per well in order to 
ensure consistency between several assays. The incubation period after plating the cells 
in the 96-well plate could be manipulated to ensure the same number of cells were being 
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used in each well for each assay. If the incubation period was one day, fifty thousand 
cells were plated into each well. If the incubation period was two days, half as many cells 
were used (twenty-five thousand). This provided us with the same number of cells for 
each assay throughout the course of our experiment.  
 After the initial period of incubation, the desired peptides were mixed into a 1 
mg/mL solution using 990 μL of media and 10 μL of dimethylsulfoxide (DMSO). The 
A549 cells were washed again with PBS prior to dosing with the peptides. In a separate 
96-well plate, 100 μL of 1% DMSO in media solution was placed in each of the wells 
corresponding to the wells of the plate containing the A549 cells. Each well was filled 
except for the first column of the plate. In this column, 200 μL of the highest 
concentration of the peptide solution (1mg/mL) was placed. A serial dilution of 100 μL 
of peptide solution was performed across each row until all of the corresponding wells 
had the required concentration of peptide present (figure 3). Then the peptides were 
transferred in their diluted concentrations to the corresponding wells containing the A549 
cells. This original 96-well plate was incubated for an additional period of 48 hours. 
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Figure	4:	Peptide	serial	dilution	process	with	the	well	concentrations[	1.0,	0.50,	0.25,	0.125,	0.0625,	0.0313,	0.0156,	0.0078	(mg/mL)]	of	peptide	
1.0	 0.50	 0.25	 0.125	 0.0625	 0.0313	 0.0156	 0.0078	
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2.4.1 MTT Assay 
 The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
tetrazolium assay is a reduction assay that utilizes time-dependent reduction and 
absorbance to measure cell viability. The MTT tetrazolium starting material is added in 
uniform concentration (5mg/mL in PBS) to each well. This initiates a time-dependent 
reduction of the tetrazolium into a formazan product (Figure 4). The amount of formazan 
product present in the well is proportional to the number of metabolically active cells 
(viable cells) left in the well. After a 3—4 hours incubation period, protected from any 
light via aluminum foil wrapping, the MTT substrate was finished reacting and the 96-
well plate was taken to a spectrophotometer. 
  The 96-well plate was placed into the Biotek Synergy2 plate reader. The plate 
was read using the plate reader with analysis performed on the Gen5 software. The well 
plate was set to shake in the reader for 5 minutes and the absorbance was read at 570 nm. 
Multiple readings over various months of testing were compiled into averages. The cell 
viability was plotted against the peptide concentration to determine the IC50 value of each 
peptide. 
 
 
Figure	5:	Reduction	of	MTT	tetrazolium	to	formazan	product	
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2.4.2 Hyaluronidase Assay 
 To test whether or not the cell-death initiated by the peptides is due to a 
hyaluronan-binding mechanism, the cells were initially treated with hyaluronidase prior 
to dosing. Hyaluronidase is the enzyme that degrades hyaluronan. Five μL of a 0.1 
mg/mL hyaluronidase in PBS solution was prepared and added to each well of the 96-
well plate prior to the dosing of the peptides. After being added, the 96-well plate was 
incubated for a 1 hour period at 37 °C with 5% CO2 in humidified air and then the 
peptide dosing protocol began again with 0.1mg/mL concentration in a control set as well 
as duplicate sets of All D-CDT and the standard form of CDT. The same MTT assay as 
described in Section 2.4.1 was followed again to plot the cell viability against the peptide 
concentrations. This, again, provided the IC50 values of the peptides. 
 
2.4.3 Apoptosis Assay 
 In order to better understand the relationship between caspase activation and the 
dosed peptides an apoptosis assay kit was purchased from Thermo Fisher Scientific. The 
Pierce Cleaved Caspase-3 Colorimetric In-Cell ELISA Kit measures the activity of 
caspase-3; this is a protease whose activation is a key step in the apoptosis pathway in 
mammalian cells.  
 To find the amount of active caspase-3 approximately 0.1 x 105 cells were plated 
in a 96-well plate, in quadruplicates. The All D-CDT was incubated in each well for 72 
hours. This lead to the averaging of 4 rows of wells, versus one control well. After this 
period, the cell media was removed and the cells were fixed with 4% formaldehyde and 
made permeable with a procession of solutions described by the manufacturer. The 
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primary anti-cleaved caspase-3 antibody was added into the solution and the cells were 
incubated for 24 hours at 4 °C. After this period a diluted horseradish peroxidase (HRP) 
conjugate was added and incubated at room temperature for 30 minutes. This was 
removed and after a period of washing the TMB substrate (3,3’,5,5’-
Tetramethylbenzidine; a visualizing agent acting as a hydrogen donor to the HRP 
conjugate) was added, which created a blue color in the micro-wells. A TMB stop 
solution was used after 15 minutes. After 30 minutes the Biotek Synergy2 plate reader 
was used to measure absorbance at 450 nm. 
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Chapter 3: Results and Discussion 
3.1 Peptide Synthesis and Purification results 
 The HPLC results showed four analogs with the desired purity of >99%. Mass 
spectrometry data confirmed these analogs by their molecular weights. The resulting 
molecular weights are listed with the amino acid sequence and the name of the peptides 
in Table 1. These were the five peptides we incorporated in our MTT assays. The serine 
negative control is not included in this table being that it is a known negative control and 
was not expected to inhibit cell growth in the cancer cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analog Sequence 
Molecular 
Weight (Da)a 
HPLC 
Purity 
(%)b 
CDT KWFRVYRGIYRRR 1855.2 99 
Reverse D-CDT rrryigryvrfwk 1855.2 99 
Reverse CDT RRRYIGRYVRFWK 1855.1 99 
D-CDT kwfrvyrgiyrrr 1855.1 99 
Table	1:	CDT	Peptide	Sequences	with	HPLC	purities	
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3.2 MTT Assay Results 
 The analogs of CDT from Table 1 were dosed into the 96-well plate and read by 
the Biotek Synergy2 plate reader. The blank wells consisted of 100 µL of cell media with 
1% DMSO. The absorbance of the blank was subtracted from all absorbance values and 
the value with the least corrected absorbance, creating the highest absorbance value, was 
defined as 100% viable cells.   
 GraphPad prism was used to determine IC50 values. After establishing the IC50 
values through GraphPad Prism it was possible to move further and test the most 
effective peptide in different assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
All	D-CDT	(kwfrvyrgiyrrr)			
Figure	6:	Cell	viability	plot	of	the	All	D	form	of	CDT.		
Peptide	Concentration	(μM)	
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Reverse	D-CDT	(rrryigryvrfwk)		
Figure	7:	Plot	of	the	Reverse	D	form	of	CDT.	
Peptide	Concentration	(μM)	
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Figure	8:	A549	cell	viability	of	different	CDT	analogs		Peptide	Concentration	(μM)	
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Name SEQUENCE IC50 Values (µM) 
CDT KWFRVYRGIYRRR >550 
Reverse D-CDT rrryigryvrfwk 90 
Reverse CDT RRRYIGRYVRFWK >550   
All D-CDT kwfrvyrgiyrrr 9.814 
Serine 1,4,7,11,12,13-CDT SWFSVYSGIYSSS >550 
 
 The averaged data allowed for the plotting of the cell viability plots (Figures 6, 7, 
and 8). Five analogs of CDT were tested against the cell line and the measured 
absorbance indicated the level of cell survival. Initially the most promising result came 
from the All D form of CDT. It had been suggested from previous research (Lifetein, 
2017; Kreill, 1997) that the D-form of certain peptides might increase the potency when 
compared to the L-form, partly due to the fact that human cells consist of L-forms of 
peptides, and therefore the D-forms are not recognized by peptidases that may break 
down the peptide analogs (See section 1.2.1.). Figure 6 shows the effect resulting from 
the All D peptide. From this plot the IC50 (the concentration needed for 50% inhibition of 
cell survival) was calculated to be 9.814 µM. From the data accumulated, this peptide 
clearly showed the greatest level of efficacy against the A549 cancer cells.  This 
stimulated the interest for further testing of the All D form in the hope of understanding 
the mechanism behind its anticancer ability. 
Table	2:	The	measured	IC50	of	the	analogs	of	CDT	
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 The second plot (Figure 7) displayed the efficacy of the reverse-D CDT analog.  
This plot reinforced the notion that D-form peptides may have greater potency in terms of 
their anticancer properties. The reverse-D form proved to also be effective against the 
A549 cancer cells, with an IC50 tabulated at 90 µM. An attempt to narrow down the 
probable mechanistic pathways could prove beneficial to the overall understanding of 
tachyplesin’s abilities; however that aspect was not fully researched in this work. In 
comparison to the remaining three peptides, the reverse-D form was considered effective 
in inhibiting the survival of the A549 cancer cells, but the All D-CDT had an efficacy 
nearly tenfold greater. This proved more worthy of further investigation. 
 The final plot (Figure 8) showed the least effective CDT analogs. For one of the 
peptides of this plot, the Serine-CDT, this was an expected outcome, since the Serine-
CDT analog was predicted to act as a negative control for the experiment because all of 
the positively charged residues were replaced with serine residues. However, more 
surprisingly, the standard form of CDT and the reverse-CDT were also both ineffective 
against the A549 cell line. 
 Previous groups that have studied the anticancer effects of tachyplesin have 
reported an IC50 of 33 µM when tested against the TSU human prostate cancer cell line 
(Chen et al., 2001). When compared to our MTT results it appears that the cysteines in 
tachyplesin are necessary for its efficacy, when in the L-form. Being that CDT is a new 
molecule of interest in anticancer research, it has not been assayed against cancer and 
only thought to plausibly be effective against cancer due to tachyplesin’s known efficacy. 
Despite CDT’s inability to diminish cell viability, the All D-CDT form showed a greater 
IC50 than the previously reported value of tachyplesin. These newly synthesized analogs 
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have also not been tested for the antibacterial qualities that CDT has been well assayed 
for.  
 These results also suggest that when synthesizing other analogs of CDT it may be 
beneficial to preferentially synthesize the D-form over the L-form. Table 2 clearly 
displays the differences in IC50 values between each of the analogs tested. The lowest 
value reflected the greatest ability to inhibit the cell survival of the A549 cancer cells. 
This was observed in the D-form of CDT, while the next best came in the reverse-D 
form. The remaining three had calculated IC50 values greater than 550 µM—a value not 
considered potent enough for inhibition treatments of cancer. After it was seen that the D-
form of CDT had the greatest ability to diminish cell survival rates, other assays were 
prepared to try to determine its mechanism. 
 
3.2 Hyaluronidase Assay Results 
 CDT and All D-CDT were tested against one another to help understand whether 
or not the D-form versus L-form configuration had an impact on possible interactions 
with hyaluronan, while also examining All D-CDT for a change in efficacy compared to 
the MTT results. If the results yielded a discrepancy between the two forms, not only 
would the mechanistic understanding of how the peptides function improve, it would also 
be possible to see which form was likely to be more effective through this pathway. If the 
cell viability plots appeared to be similar to the plots that were obtained for the MTT 
assay, this would mean that the All D form operated independently of hyaluronan, 
meaning it could still diminish cell survival rate even after the hyaluronan was degraded 
into smaller oligomers. It was unexpected for the CDT to become more effective after the 
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hyaluronan was degraded, unless hyaluronan had an inhibitory effect on the L-form of 
these peptides.  
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Figure	9:	Cell	viability	plot	of	the	All	D	form	of	CDT	after	hyaluronan	degradation	
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All D-CDT had much less of an effect on cell viability after hyaluronidase 
treatment (Figure 9) than before (Figure 6). The MTT data gave an IC50 of 9.814 µM 
while the hyaluronan was still intact. After the use of hyaluronidase, degrading the pro-
cancer hyaluronan into smaller oligomer fractions, the IC50 value for the All D-CDT form 
increased to greater than 550 µM. This made it no more effective than our control, the 
Serine-CDT form. This higher IC50 value suggests that the All D-CDT peptide is 
interacting with the hyaluronan in order to inhibit cell growth. 
It has been reported that certain oligomers of degraded hyaluronan do have pro-
cancer effects even though the hyaluronan itself is no longer functioning (Kultti et al., 
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Figure	10:	Cell	viability	plot	of	CDT	after	hyaluronan	degradation.	
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2012). However, each well was washed with a phosphate buffer solution immediately 
before being dosed with the peptides, which minimized the possibility of oligomer 
fractions interacting with the All D-CDT when it was dosed. Because of this, the most 
likely interpretation of this data is that the hyaluronan and the All D-CDT peptide interact 
with one another. 
 The standard CDT form showed no change in its ability to affect the cancer cells 
after hyaluronidase pretreatment, retaining an IC50 greater than 550 µM. This data does 
not rule out that CDT interacts with hyaluronan. CDT likely has a much shorter half life 
than All D-CDT, which could mean that it does not survive long enough to interact with 
hyaluronan. It may have the same interactions as the All D-CDT form. 
 
3.3 Apoptosis Assay 
 The apoptosis assay measures the activation of caspase-3, a key apoptosis 
activation factor, through absorbance measurements. A greater amount of absorbance in a 
given well would indicate a greater level of caspase-3 activation, and a greater amount of 
apoptosis occurring in the cells. This data is different from the previous graphics 
represented in this report (Figure 6—8, Figure 9, and Figure 10, being that it is not 
directly measuring cell viability, but it is specifically measuring the amount of caspase-3 
activity within the well (it is an excitatory measurement, rather than an inhibitory 
measurement). These measured values of apoptosis percentages were plotted in Figure 
11.  This data suggests that the All D-CDT peptide can induce apoptosis within the A549 
lung cancer cells via caspase-3 activation, albeit at concentrations > 100 µM, which far 
exceed those required to obtain an IC50 of 9.814 µM (Figure 6). There are different routes 
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that may activate caspase-3 by cleavage of its pro-caspase-3 form. A large, more general, 
route comes from extracellular apoptotic triggers, which free Cytochrome-C (Cyt-C) 
from binding with the mitochondrion. This allows Cyt-C to activate caspase-9 via the 
activation of apoptotic protease activating factor-1 (APAF 1). Caspase-9 can cleave the 
pro-domain from pro-caspase-3, activating caspase-3 and inducing apoptosis (McDonald 
et al., 2003). It is plausible that the All D-CDT analog is inducing this pathway. This 
becomes even more plausible due to the perceived binding relationship between All D-
CDT and hyaluronan, understood via the hyaluronidase assay performed (Section 3.2). 
The extracellular matrix concentration of hyaluronan is increased in cancer cells (Kullti et 
al., 2012). It is thought to promote angiogenesis and inhibit cell death (Ruffle et al., 
2008). If All D-CDT is having an inhibitory effect on hyaluronan it is likely increasing 
extracellular stress on the cancer cells, which then induces activation of the caspase-3 
apoptosis pathway. But, due to its EC50 (needed peptide concentration to excite 50% of 
caspase-3/apoptosis) being greater than 100 µM it is possible that All D-CDT’s 
interaction with hyaluronan is creating one of the aforementioned AMP pathways to cell 
death (Section 1.1.1), which could lead to necrosis rather than apoptosis. 
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Figure	11:	Percentage	of	A549	apoptosis	increase	as	a	function	of	increasing	All	D-CDT	concentration.			
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Chapter 4: Future Research 
 Due to limitations in the amount of different analogs available, the reverse-D 
CDT was not assayed in full with the All D-CDT form. Since the results have suggested 
some potency for this analog it is going to be necessary to examine the reverse-D form 
more extensively for the main purpose of comparing the efficacy of the D-form versus 
the L-form. From what was seen in the initial MTT absorbance assays, the reverse-D 
peptide was more effective than any of the L-form peptides used.  Even though the 
reverse-D CDT is not as effective against the cancer cells as the All D-CDT, an apoptosis 
assay could further differentiate the effects of the D-forms versus the L-forms when 
characterized against the reverse-L form. 
 Another route for deeper understanding of the effectiveness of these different 
analogs would come in the form of a different cell line. The A549 adenocarcinoma lung 
cancer cells have allowed the observation that these analogs have activity against lung 
cancer, but another cancer cell line could help differentiate the ability of the analogs 
dependent on the type of cancer they are exposed to. One of the most famous cell lines is 
the HeLa cell line—stemming from cervical cancer. This cell line has been used in tens 
of thousands of biochemical publications (Landry et al., 2013). Being that it is widely 
known and credible, testing the peptide analogs against these cells, under the same 
condition as the A549 lung cancer cells, would give more substantial data and possible 
increased credibility to the efficacy of the All D-CDT peptide. 
 In addition, a time delay assay could be incorporated where we would culture 
three 96-well plates in the same manner as mentioned in section 2.4.1. The cells in the 
96-well plate would be dosed with All D-CDT via serial dilution. An MTT assay would 
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be run every 24 hours over a period of three days. In a new cell line, such as the HeLa 
cells, a time delay assay with the All D-CDT analog would provide the same information; 
it would generate a greater understanding of the time component of its efficacy so that its 
effect could be maximized.  Ultimately, this information could lead to the development of 
a new treatment for certain types of cancer.   
 It would be valuable to further our understanding of All D-CDT’s impact on 
apoptosis. Specifically we should study the different caspases known to promote 
apoptosis and try to conclude whether or not All D-CDT has any implicit effects on the 
caspases’ activation. Even though it was clear that in high enough concentrations All D-
CDT could activate the caspase-3 apoptotic pathway it may take a much lower 
concentration to activate a different caspase. 
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